Filter
2855
Featured
477
432
Language
Document type
663
588
380
301
260
135
89
87
84
81
79
76
17
10
5
Countries / Regions
251
88
50
45
42
37
36
34
33
31
28
26
22
22
21
20
20
20
20
19
19
19
17
17
16
15
15
15
14
12
12
12
11
11
10
10
9
9
8
8
7
7
6
6
6
6
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
170
133
81
61
58
54
52
50
48
46
42
35
32
32
32
31
31
29
28
27
27
26
26
25
25
25
23
22
22
19
19
19
19
18
18
17
17
17
16
16
15
14
14
13
13
13
13
12
12
12
12
12
12
12
11
11
11
11
11
10
10
10
10
10
9
9
9
9
8
8
8
8
7
7
7
6
6
6
6
6
6
6
6
5
5
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Toolboxes
89
86
74
55
50
48
38
38
38
38
38
35
35
32
31
31
31
30
30
29
28
27
27
26
25
25
24
22
21
21
21
20
20
20
20
19
18
18
18
18
18
17
16
16
16
16
16
15
15
15
15
14
14
14
14
14
14
14
14
14
14
14
13
13
13
13
13
13
13
13
13
13
13
13
12
12
12
12
12
12
12
12
12
12
12
11
11
11
11
11
11
11
11
11
11
11
11
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
23 March 2021
The meeting addressed the last key area, that is, determining the best method or combination of diagnostic methods for a control programme for S. stercoralis infections in humans.
Dr Montresor’s presentation highlighted that while there is currently no “gold standard” for the
...
n light of the potential risk posed by SARS-CoV-2 variants, in January 2021 WHO organized an ad hoc consultation to discuss the development of an R&D agenda in response to existing and emerging SARS-CoV-2 variants.
The key objectives were to identify the critical research questions related to var
...
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
COVID-19 vaccines are safe, and getting v
...
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Vaccines are a critical tool in the battl
...
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Countries around the world are rolling ou
...
COVID-19 Vaccines: 1 Safety Surveillance 2 Manual
While there is no indication that pregnant women have an increased susceptibility to infection with SARS-CoV-2, there is evidence that pregnancy may increase the risk of severe illness and mortality from COVID-19 disease in comparison with non-pregn
...
Evaluation of COVID-19 vaccine effectiveness
17 March 2021
7 April 2021
Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed.
Available in Englisch, French and Russian
1 April 2021
In our unequal world, how does inequity impact our fight against COVID-19? How can we address it? WHO’s Dr Mariângela Simao explains in Science in 5 this week.
Learn what scientists look for in the different phases of a clinical trial for a vaccine. What does it mean when a vaccine trial is halted due to an adverse event? WHO’s Dr Kate O’Brien explains in Science in 5 this week
Vaccines are designed to give you immunity without the dangers of getting the disease. It’s common to experience some mild to moderate side effects when receiving vaccinations. This is because your immune system instructs your body to increase blood flow so more immune cells can circulate, and it
...
The WHO COVID-19 Essential Supplies Forecasting Tool (ESFT) assists governments, partners, and other stakeholders to forecast the necessary volume of personal protective equipment, diagnostic equipment, consumable medical supplies, biomedical equipment for case management, and essential drugs for su
...
13 April 2021 Policy Brief
How much protection does the current batch of COVID-19 vaccines provide us? Would you need a booster shot for new variants? What does science and evidence tell us about mass gatherings and the spread of COVID-19?
WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5 this week.
People with asthma (PWA) generally are considered at higher risk from respiratory infections, as is seen annually with influenza. At the outset of the COVID-19 pandemic, PWA were widely assumed to be at increased risk from COVID-19. However, as data emerged throughout 2020, the association between a
...
Available in Chinese, English, French, Russian and Spanish; WHO and UNICEF policy brief, 19 April 2021
Persons with disabilities are disproportionately impacted by COVID-19, both directly because of infection, and indirectly because of restrictions to reduce the spread of the virus. Persons with di
...
Member States have requested WHO policy guidance on how to facilitate the implementation of national AMS activities in an integrated and programmatic approach. This policy guidance responds to that demand from Member States and is anchored in public health guiding principles in the human health sect
...
This resource explains how WHO EUL COVID-19 vaccines without vaccine vial monitor or VVM should be handled at the vaccination site, to ensure that safe and potent vaccines are administered.
This document has been updated: 31 August 2021
